Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the fir ...

PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the first quarter of 2025. "In the first quarter, we made progress towards c ...

The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's CYTK aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26 from September 26.The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company's proposed Risk Evaluation and Mitigation Strategy (REMS).Also Read: Bristol Myers Analyst Says FDA Update Is ...

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26, 2025. The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company’s proposed ...

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor conferences in May: The Citizens Life Sciences Conference: Members of the management team will participate in a fireside chat on Wednesday, May 7, 2025 at 10:00 AM Eastern Time at the New York Hilton Midtown Hotel in New York, NY.2025 RBC Capital Markets Global Healthcare Conference: Members of the management team wil ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 24 Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 2:15 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay wi ...

Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 15.7% loss over the past four weeks.The company has made good pipeline progress of late. Lead candidate aficamten is under review in the United States for the treatment of obstructive hypertrophic cardiomyopathy. Other pipeline candidates are also advancing well.This biopharm ...

Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) --  Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and Health Outcomes in HCM), an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic institutions, that leverages real-world, d ...

New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramideand Longer-Term Effect on Cardiac Structure and Function SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic cardiomyopathy (HCM), at the American College of Cardiology (ACC) Annual Scientific Session ...

Company Overview - Cytokinetics, Incorporated (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on developing therapies for heart failure, neuromuscular disorders, and hypertrophic cardiomyopathy (HCM) [1] Commercialization Progress - The company is rapidly advancing towards the commercialization phase of its drug Aficamten, indicating a significant shift from clinical development to market readiness [1]